Research

The Single-Domain Antibody Technology

Smivet focuses on the SDA technology, because of its excellent safety and efficacy profile, its broad therapeutic scope and the excellent development properties. The SDA technology was discovered and developed by the Vrije Universiteit Brussel in Belgium in the 90’s of the previous century. SMIVETs  aim was to translate the technology developed in human medicine and make it fit for purpose for animal health. The technology has recently been reviewed by several experts in the field of single-domain antibodies also named VHH ( Muyldermans (2020), Arbabi-Gharoudi M (2017) ).

Smivet is located in the Netherlands in close vicinity of several Dutch research centers in Agrifood (Wagening University), Animal Health (Utrecht University) and Human Health (Radboud University). However, Smivet can establish a cooperation with any center of excellence for a certain topic worldwide.

Smivet BV its internal research project pipeline (started in 2015) targets currently 3 different areas concerning multiple animal species. For the first research project proof of concept has been reached in 2019 after a successful clinical study in horses. Research is performed by internal and external resources such as Contract Research Organisation's (CROs), Institutes & Universities.

For Smivet the (partial) ownership of IP is considered as a standard part of the research performed.